KCKevin Cain

Kevin Cain

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kevin Cain has a total of 30 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Gut microbiome and symptoms in females with irritable bowel syndrome: a cross-sectional analysis

    by K.J. Kamp, A.M. Plantinga, K.C. Cain, R.L. Burr, C.-S. Tsai, Q. Wu, S.Y. So, S. Badu, T. Savidge, R.J. Shulman, et al.

    Irritable bowel syndrome (IBS), a disorder of gut-brain interaction, is associated with abdominal pain and stool frequency/character alterations that are linked to changes in microbiome composition. We tested whether taxa differentially abundant between females with IBS vs healthy control females (HC) are associated with daily gastrointestinal and psychological symptom severity. Participants (age 18-50 year) completed a 3-day food record and collected a stool sample during the follicular phase. They also completed a 28-day diary rating symptom intensity; analysis focused on the three days after the stool sample collection. 16S rRNA gene sequencing was used for bacterial identification. Taxon abundance was compared between IBS and HC using zero-inflated quantile analysis (ZINQ). We found that females with IBS (n = 67) had greater Bacteroides abundance (q = 0.003) and lower odds of Bifidobacterium presence (q = 0.036) compared to HC (n = 46) after adjusting for age, race, body mass index, fibre intake, and hormonal contraception use. Intestimonas, Oscillibacter, and Phascolarctobacterium were more often present and Christensenellaceae R-7 group, Collinsella, Coprococcus 2, Moryella, Prevotella 9, Ruminococcaceae UCG-002, Ruminococcaceae UCG-005, and Ruminococcaceae UCG-014 were less commonly present in IBS compared to HC. Despite multiple taxon differences in IBS vs HC, we found no significant associations between taxon presence or abundance and average daily symptom severity within the IBS group. This may indicate the need to account for interactions between microbiome, dietary intake, metabolites, and host factors.


  • Open Access

    A Comprehensive Self-Management Intervention for Inflammatory Bowel Disease (CSM-IBD): Protocol for a Pilot Randomized Controlled Trial

    by Kendra Kamp, Kindra Clark-Snustad, Linda Yoo, Samantha Winders, Kevin Cain, Rona L Levy, Neelendu Dey, Scott Lee, Laurie Keefer, Margaret Heitkemper

    Background: Despite pharmacological treatment, individuals with inflammatory bowel disease (IBD) experience a variety of symptoms, including abdominal pain, fatigue, anxiety, and depression. Few nonmedical self-management interventions are available for people with IBD. A validated comprehensive self-management (CSM) intervention is effective for patients with irritable bowel syndrome who can have symptoms similar to those of individuals with IBD. We created a modified CSM intervention tailored to individuals with IBD (CSM-IBD). The CSM-IBD is an 8-session program delivered over 8-12 weeks with check-ins with a registered nurse. Objective: The primary objective of this pilot study is to determine the feasibility and acceptability of study procedures and the CSM-IBD intervention and to evaluate preliminary efficacy on quality of life and daily symptoms for a future randomized controlled trial. Additionally, we will examine the association of socioecological, clinical, and biological factors with symptoms at baseline and response to intervention. Methods: We are conducting a pilot randomized controlled trial of the CSM-IBD intervention. Participants aged 18-75 years who are experiencing at least 2 symptoms are eligible for inclusion. We plan to enroll 54 participants who will be randomized (2:1) into the CSM-IBD program or usual care. Patients in the CSM-IBD program will have 8 intervention sessions. Primary study outcomes include the feasibility of recruitment, randomization, and data or sample collection, as well as the acceptability of study procedures and interventions. Preliminary efficacy outcome variables include quality of life and symptoms. Outcomes data will be assessed at baseline, immediately post intervention, and 3 months post intervention. Participants in the usual care group will have access to the intervention after study participation. Results: This project is funded by the National Institutes of Nursing Research and reviewed by the University of Washington’s institutional review board. Recruitment began in February 2023. As of April 2023, we have enrolled 4 participants. We expect the study to be completed by March 2025. Conclusions: This pilot study will evaluate the feasibility and efficacy of a self-management intervention (a web-based program with weekly check-ins with a registered nurse) that aims to improve symptom management in individuals with IBD. In the long term, we aim to validate a self-management intervention to improve patient quality of life, reduce direct and indirect costs related to IBD, and be culturally appropriate and accessible, particularly in rural and underserved communities. Trial Registration: ClinicalTrials.gov NCT05651542; https://clinicaltrials.gov/ct2/show/NCT05651542 International Registered Report Identifier (IRRID): PRR1-10.2196/46307


  • Open Access

    A Comprehensive Self-Management Intervention for Inflammatory Bowel Disease (CSM-IBD): Protocol for a Pilot Randomized Controlled Trial (Preprint)

    by Kendra Kamp, Kindra Clark-Snustad, Linda Yoo, Samantha Winders, Kevin Cain, Rona L Levy, Neelendu Dey, Scott Lee, Laurie Keefer, Margaret Heitkemper

    BACKGROUND Despite pharmacological treatment, individuals with inflammatory bowel disease (IBD) experience a variety of symptoms, including abdominal pain, fatigue, anxiety, and depression. Few nonmedical self-management interventions are available for people with IBD. A validated comprehensive self-management (CSM) intervention is effective for patients with irritable bowel syndrome who can have symptoms similar to those of individuals with IBD. We created a modified CSM intervention tailored to individuals with IBD (CSM-IBD). The CSM-IBD is an 8-session program delivered over 8-12 weeks with check-ins with a registered nurse. OBJECTIVE The primary objective of this pilot study is to determine the feasibility and acceptability of study procedures and the CSM-IBD intervention and to evaluate preliminary efficacy on quality of life and daily symptoms for a future randomized controlled trial. Additionally, we will examine the association of socioecological, clinical, and biological factors with symptoms at baseline and response to intervention. METHODS We are conducting a pilot randomized controlled trial of the CSM-IBD intervention. Participants aged 18-75 years who are experiencing at least 2 symptoms are eligible for inclusion. We plan to enroll 54 participants who will be randomized (2:1) into the CSM-IBD program or usual care. Patients in the CSM-IBD program will have 8 intervention sessions. Primary study outcomes include the feasibility of recruitment, randomization, and data or sample collection, as well as the acceptability of study procedures and interventions. Preliminary efficacy outcome variables include quality of life and symptoms. Outcomes data will be assessed at baseline, immediately post intervention, and 3 months post intervention. Participants in the usual care group will have access to the intervention after study participation. RESULTS This project is funded by the National Institutes of Nursing Research and reviewed by the University of Washington’s institutional review board. Recruitment began in February 2023. As of April 2023, we have enrolled 4 participants. We expect the study to be completed by March 2025. CONCLUSIONS This pilot study will evaluate the feasibility and efficacy of a self-management intervention (a web-based program with weekly check-ins with a registered nurse) that aims to improve symptom management in individuals with IBD. In the long term, we aim to validate a self-management intervention to improve patient quality of life, reduce direct and indirect costs related to IBD, and be culturally appropriate and accessible, particularly in rural and underserved communities. CLINICALTRIAL ClinicalTrials.gov NCT05651542; https://clinicaltrials.gov/ct2/show/NCT05651542 INTERNATIONAL REGISTERED REPORT PRR1-10.2196/46307

  • Tu1381: TRYPTOPHAN FUNCTIONAL CAPABILITY AND BIFIDOBACTERIUM ABUNDANCE AND THEIR RELATIONSHIP TO ANXIETY AND DEPRESSIVE SYMPTOMS IN WOMEN WITH AND WITHOUT IRRITABLE BOWEL SYNDROME

    by Miriam Levy, Anna M. Plantinga, Kendra Kamp, Li Juen Chen, Linda Yoo, Kevin Cain, Robert Burr, Robert J. Shulman, Margaret Heitkemper

  • Tu1565: RELATIONSHIP BETWEEN ESCHERICHIA/SHIGELLA AND ABDOMINAL PAIN AMONG WOMEN WITH IRRITABLE BOWEL SYNDROME

    by Linda Yoo, Kendra Kamp, Li Juen Chen, Kevin Cain, Robert Burr, Sik Yu So, Shyam Badu, Qinglong Wu, Tor C. Savidge, Robert J. Shulman, et al.


  • Open Access

    Computation & cultural heritage

    by Benedict Brown, Kevin Cain, Paolo Cignoni, Paul Debevec, Greg Downing, Mashhuda Glencross

    This course surveys several practical techniques advanced by graphics and vision researchers for applications in cultural heritage, archeology, and art history. Topics include: efficient techniques for digital capture of heritage objects, appropriate uses in the heritage field, an end-to-end pipeline for processing archeological reconstructions (with special attention to incorporating archeological data and review throughout the process), how digital techniques are actually used in cultural heritage projects, and an honest evaluation of progress and challenges in this field.